 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
98 News |  |
| 12» |
- | methimazole / Generic mfg., elezanumab (ABT-555) / AbbVie
Preclinical, Journal: Elezanumab Accelerates Post-Injury Regeneration of Olfactory Sensory Neurons in a Methimazole-Induced Mouse Model. (Pubmed Central) - Aug 29, 2025
Repulsive guidance molecule A blockade increases GAP43+ and OMP+ cells dorsally while sparing basal cells. This approach offers a novel therapy for sensorineural olfactory disorder.
- || elezanumab (ABT-555) / AbbVie
Clinical, Journal: Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis. (Pubmed Central) - Aug 28, 2025
Elezanumab was safe and well tolerated, but did not meet the primary endpoint in either study. ANN NEUROL 2025;98:590-602.
- || elezanumab (ABT-555) / AbbVie
Trial primary completion date: ELASCI: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (clinicaltrials.gov) - Jul 7, 2025
P2, N=60, Active, not recruiting, Sponsor: AbbVie
ANN NEUROL 2025;98:590-602. Trial primary completion date: May 2025 --> Jan 2026
- elezanumab (ABT-555) / AbbVie
ELEZANUMAB IN ACUTE ISCHAEMIC STROKE: RESULTS FROM A 52-WEEK, PHASE 2A, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (Hall 3E) - Jun 2, 2025 - Abstract #ESOC2025ESOC_1290;
P2
Trial primary completion date: May 2025 --> Jan 2026 This study evaluates the preliminary efficacy and safety of elezanumab for the treatment of moderate- to-severe acute ischemic stroke.
- || elezanumab (ABT-555) / AbbVie
Review, Journal: Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update. (Pubmed Central) - Apr 17, 2025
Evidence from preclinical studies associate RGMa overexpression with negative outcomes, such as increased neuroinflammation and synaptic loss, while RGMa inhibition, particularly the use of agents like elezanumab, has shown promise in enhancing neuronal survival and functional recovery...We emphasize RGMa's critical role in CNS pathology and its potential to pave the way for innovative treatment strategies in neurological disorders. While preclinical findings are encouraging so far, further clinical trials are needed to validate the safety and efficacy of RGMa-targeted therapies.
- ||| elezanumab (ABT-555) / AbbVie
Trial completion: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Jan 9, 2025
P2, N=121, Completed, Sponsor: AbbVie
While preclinical findings are encouraging so far, further clinical trials are needed to validate the safety and efficacy of RGMa-targeted therapies. Active, not recruiting --> Completed
- || elezanumab (ABT-555) / AbbVie
Trial primary completion date: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Jun 19, 2024
P2, N=121, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Trial primary completion date: Jan 2025 --> Apr 2024
- || elezanumab (ABT-555) / AbbVie
Enrollment closed: ELASCI: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (clinicaltrials.gov) - Jun 9, 2024
P2, N=54, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Jan 2025 --> Apr 2024 Recruiting --> Active, not recruiting
- || elezanumab (ABT-555) / AbbVie
PK/PD data, Journal: Comparability of Elezanumab Safety, Tolerability, and Pharmacokinetics in Healthy Japanese, Chinese, and White Participants. (Pubmed Central) - Feb 5, 2024
All adverse events were assessed by the investigator as having no reasonable possibility of being related to the study drugs and were mild in severity. No positive immunogenicity effect was observed that impacted elezanumab exposure or safety.
- || elezanumab (ABT-555) / AbbVie
Trial primary completion date: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Jun 27, 2023
P2, N=121, Active, not recruiting, Sponsor: AbbVie
No positive immunogenicity effect was observed that impacted elezanumab exposure or safety. Trial primary completion date: May 2024 --> Jan 2025
- || elezanumab (ABT-555) / AbbVie
Enrollment closed, Trial completion date, Trial primary completion date: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Jun 8, 2023
P2, N=121, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: May 2024 --> Jan 2025 Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Feb 2025 | Trial primary completion date: Aug 2023 --> May 2024
- || elezanumab (ABT-555) / AbbVie
Trial primary completion date: ELASCI: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (clinicaltrials.gov) - Feb 28, 2023
P2, N=54, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Feb 2025 | Trial primary completion date: Aug 2023 --> May 2024 Trial primary completion date: Aug 2023 --> Jul 2025
- elezanumab (ABT-555) / AbbVie
Elezanumab Decreases Neuronal Damage And Improves Functional Recovery In A Rabbit Model Of Permanent Middle Cerebral Artery Occlusion (Hall F, Poster Hall; MP110) - Feb 7, 2023 - Abstract #ISC2023ISC_1493;
Collectively, these data support a neuroprotective role for elezanumab in this translational model of acute ischemic stroke. Elezanumab is now being tested in a Phase 2a clinical trial for acute ischemic stroke.
- | elezanumab (ABT-555) / AbbVie
Trial completion date: ELASCI: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (clinicaltrials.gov) - Dec 6, 2022
P2, N=54, Recruiting, Sponsor: AbbVie
Elezanumab is now being tested in a Phase 2a clinical trial for acute ischemic stroke. Trial completion date: May 2024 --> Apr 2026
- elezanumab (ABT-555) / AbbVie
Baseline MRI Characteristics of Multiple Sclerosis Patients Enrolled in Two Phase 2 Studies of Elezanumab (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_634;
P2
Trial completion date: May 2024 --> Apr 2026 Baseline MRI data from the two studies provided a standardized dataset to assess the MRI characteristics of the brain and cervical spinal cord in MS patients with different underlying pathologies and their relationship with clinical measures.
- || elezanumab (ABT-555) / AbbVie
P1 data, Journal: Phase 1 Evaluation of Elezanumab (anti-RGMa mAb) in Healthy and MS Participants. (Pubmed Central) - Sep 14, 2022
P1
Reduced CSF levels of free RGMa levels demonstrate central nervous system target binding of elezanumab with an apparent maximal effect at 1800mg IV. Exposure-associated increases in CSF IL-10, an anti-inflammatory cytokine with neuroprotective/neurorestorative properties, support potential pathway modulation in MS participants.
- | elezanumab (ABT-555) / AbbVie
Journal: Delayed administration of elezanumab, a human anti-RGMa neutralizing monoclonal antibody, promotes recovery following cervical spinal cord injury. (Pubmed Central) - Aug 31, 2022
Significant recovery in grip and trunk/core strength, locomotion and gait, and spontaneous voiding ability was found in rats treated with elezanumab either immediately post-injury or at 3 h post-SCI, and improvements in specific gait parameters were found when elezanumab was delayed to 24 h post-injury. We also developed a new locomotor score, the Cervical Locomotor Score, a simple and sensitive measure of trunk/core and limb strength and stability during dynamic locomotion.
- || elezanumab (ABT-555) / AbbVie
Clinical, Journal: Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule A to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. (Pubmed Central) - Mar 5, 2022
Finally, in the mouse cuprizone model, elezanumab reduces demyelination, which is consistent with its inhibitory effect on BMP signaling. Taken together, these preclinical data demonstrate that elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism, thus providing a compelling rationale for its clinical development in neurodegenerative diseases.
- || elezanumab (ABT-555) / AbbVie
Trial primary completion date: ELASCI: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (clinicaltrials.gov) - Jan 25, 2022
P2, N=54, Recruiting, Sponsor: AbbVie
Taken together, these preclinical data demonstrate that elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism, thus providing a compelling rationale for its clinical development in neurodegenerative diseases. Trial primary completion date: Apr 2022 --> Aug 2023
- | elezanumab (ABT-555) / AbbVie
Journal: Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemi-compression spinal cord injury in non-human primates. (Pubmed Central) - Jan 21, 2022
These data demonstrate that 6 months of intermittent IV administration of elezanumab, beginning within 24 h after a thoracic SCI, promotes neuroprotection and neuroplasticity of key descending pathways involved in locomotion. These findings emphasize the mechanisms leading to improved recovery of neuromotor functions with elezanumab in acute SCI in NHPs.
- elezanumab (ABT-555) / AbbVie
Phase 2a Study Of Elezanumab In Patients With Acute Ischemic Stroke (Hall B2, Poster Hall; Board No. P7) - Dec 21, 2021 - Abstract #ISC2022ISC_554;
P2
These findings emphasize the mechanisms leading to improved recovery of neuromotor functions with elezanumab in acute SCI in NHPs. This phase 2 study will evaluate safety and efficacy of elezanumab, a novel therapeutic intervention to improve neurological recovery after acute ischemic stroke.
- ||| elezanumab (ABT-555) / AbbVie
Trial completion, Enrollment change: RADIUS-P: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (clinicaltrials.gov) - Sep 16, 2021
P2, N=123, Completed, Sponsor: AbbVie
This phase 2 study will evaluate safety and efficacy of elezanumab, a novel therapeutic intervention to improve neurological recovery after acute ischemic stroke. Active, not recruiting --> Completed | N=90 --> 123
- |||| elezanumab (ABT-555) / AbbVie
Trial completion: RADIUS-R: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Sep 14, 2021
P2, N=208, Completed, Sponsor: AbbVie
Active, not recruiting --> Completed | N=90 --> 123 Active, not recruiting --> Completed
- ||| elezanumab (ABT-555) / AbbVie
Enrollment change, Trial primary completion date: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Aug 18, 2021
P2, N=120, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed N=80 --> 120 | Trial primary completion date: Nov 2021 --> Aug 2023
- | elezanumab (ABT-555) / AbbVie
Preclinical, Journal: Delayed administration of the human anti-RGMa monoclonal antibody elezanumab promotes functional recovery including spontaneous voiding after spinal cord injury in rats. (Pubmed Central) - Aug 7, 2021
In addition, all elezanumab treated rats showed earlier spontaneous voiding ability and less post-trauma bladder wall hypertrophy. Together, our data demonstrate the therapeutic efficacy of delayed systemic administration of elezanumab in a rat model of SCI, and uncovers a new role for RGMa inhibition in bladder recovery following SCI.
- elezanumab (ABT-555) / AbbVie
[VIRTUAL] Safety and efficacy of elezanumab in relapsing and progressive forms of multiple sclerosis: Results from two phase 2 studies, RADIUS-R and RADIUS-P (Stream 7 Therapy / Global views) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1289;
P2
12-month elezanumab exposure was safe and well-tolerated but did not improve physical function or reverse disability in participants with relapsing or progressive forms of MS. Investigations of elezanumab in other neurologic indications are ongoing.
- | elezanumab (ABT-555) / AbbVie
Trial completion date: ELASCI: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (clinicaltrials.gov) - Jun 22, 2021
P2, N=54, Recruiting, Sponsor: AbbVie
Investigations of elezanumab in other neurologic indications are ongoing. Trial completion date: Mar 2023 --> May 2024
- || elezanumab (ABT-555) / AbbVie
Elezanumab Any news about the above drugs success, as I thought feedback was due in April 21 ? (Twitter) - May 28, 2021
- | elezanumab (ABT-555) / AbbVie
Trial completion date: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - May 27, 2021
P2, N=80, Recruiting, Sponsor: AbbVie
Trial completion date: Mar 2023 --> May 2024 Trial completion date: Feb 2023 --> May 2024
- elezanumab (ABT-555) / AbbVie
[VIRTUAL] Study Design and Baseline Characteristics in Phase 2 Studies of Elezanumab, a Potential Neurorestorative Therapy for Multiple Sclerosis () - Mar 18, 2021 - Abstract #AAN2021AAN_1551;
P2
Trial completion date: Feb 2023 --> May 2024 RADIUS-R and RADIUS-P are phase 2 studies investigating safety and efficacy of elezanumab, including ecologically valid physical activity measured with wireless biosensors.
- || temelimab (GNbAC1) / GeNeuro, elezanumab (ABT-555) / AbbVie
So too early for off label use / early access/ compassionate use. Next best thing is intermittent fasting? Also interested in results of alpha lipoic acid, elezanumab and also temelimab. (Twitter) - Mar 16, 2021
- || elezanumab (ABT-555) / AbbVie
Trial initiation date: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Nov 13, 2020
P2, N=80, Recruiting, Sponsor: AbbVie
RADIUS-R and RADIUS-P are phase 2 studies investigating safety and efficacy of elezanumab, including ecologically valid physical activity measured with wireless biosensors. Initiation date: Jun 2020 --> Nov 2020
- | elezanumab (ABT-555) / AbbVie
Trial completion date: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Oct 7, 2020
P2, N=80, Recruiting, Sponsor: AbbVie
Initiation date: Jun 2020 --> Nov 2020 Trial completion date: Sep 2022 --> Dec 2022
- || Remyielination!!!?? #BIIB061 #opicinumab @biogen #elezanumab @AbbVieUS #CNMAu8 @CleneNano #Inception5 @Roche @genentech (Twitter) - Sep 8, 2020
- || elezanumab (ABT-555) / AbbVie
Dense, but hopeful 💪 @drbarrysinger @GavinGiovannoni @prof_mouse @KlausSchmierer @AaronBosterMD @Brandon_Beaber #elezanumab https://t.co/aSZvo4I4us (Twitter) - Sep 7, 2020
- elezanumab (ABT-555) / AbbVie
[VIRTUAL] Elezanumab in patients with different disease courses of multiple sclerosis: study design and baseline analysis from two phase 2 studies () - Aug 16, 2020 - Abstract #MSDC2020MSDC_289;
P2
Trial completion date: Sep 2022 --> Dec 2022 RADIUS-R and RADIUS-P are ongoing phase 2 studies investigating safety and efficacy of elezanumab as a remyelination agent.
- elezanumab (ABT-555) / AbbVie
[VIRTUAL] Use of wearable biosensors to collect real-world patient activity data in two randomized phase 2 studies of elezanumab in multiple sclerosis () - Aug 16, 2020 - Abstract #MSDC2020MSDC_257;
P2
The objective at the completion of the studies is to determine differences between treatment groups in relation to clinical endpoints.Conclusions To our knowledge, these are the first randomized MS clinical trials to incorporate BioStamp biosensors to capture real-world activity. There was a high level of compliance to-date across study sites for the subjects that have completed one or more 7-day intervals, suggesting use is not overly burdensome.
- ||| elezanumab (ABT-555) / AbbVie
Enrollment open: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Aug 7, 2020
P2, N=80, Recruiting, Sponsor: AbbVie
There was a high level of compliance to-date across study sites for the subjects that have completed one or more 7-day intervals, suggesting use is not overly burdensome. Not yet recruiting --> Recruiting
- ||| elezanumab (ABT-555) / AbbVie
Enrollment open: ELASCI: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (clinicaltrials.gov) - Jul 26, 2020
P2, N=54, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || elezanumab (ABT-555) / AbbVie
Trial primary completion date: RADIUS-P: A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (clinicaltrials.gov) - Jun 11, 2020
P2, N=123, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2020 --> Jan 2021
- || elezanumab (ABT-555) / AbbVie
Breakthrough therapy designation: I’m hoping for an FDA breakthrough designation! #elezanumab 🥇 (Twitter) - May 14, 2020
- | elezanumab (ABT-555) / AbbVie
Any news on elezanumab? 🤞 (Twitter) - May 13, 2020
- |||| elezanumab (ABT-555) / AbbVie
New P2 trial: EAISE: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (clinicaltrials.gov) - Mar 16, 2020
P2, N=80, Not yet recruiting, Sponsor: AbbVie
- |||| elezanumab (ABT-555) / AbbVie
New P2 trial: ELASCI: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) (clinicaltrials.gov) - Mar 4, 2020
P2, N=54, Not yet recruiting, Sponsor: AbbVie
- ||| elezanumab (ABT-555) / AbbVie
Who’s going to the AAN annual meeting in Toronto this April? Very interested in the Elezanumab presentation. @AaronBosterMD @Brandon_Beaber @GavinGiovannoni https://t.co/UvxFikpzwV (Twitter) - Feb 29, 2020
- elezanumab (ABT-555) / AbbVie
Investigating The Safety And Efficacy Of Elezanumab In Two Phase 2 Studies Enrolling Patients With Different Disease Courses Of Multiple Sclerosis (Exhibit Hall A, Convention Center - Board no. P062) - Feb 21, 2020 - Abstract #ACTRIMSForum2020ACTRIMS_FORUM_236;
P2
Trial primary completion date: Sep 2020 --> Jan 2021 The RADIUS phase 2 studies are ongoing and designed to evaluate the safety and neurorestorative properties of elezanumab in patients with relapsing or progressive forms of MS.
- |||||| elezanumab (ABT-555) / AbbVie
New trial: Expanded Access to Elezanumab (clinicaltrials.gov) - Feb 19, 2020
P, N=0, Temporarily Not Available, Sponsor: AbbVie
- ||| elezanumab (ABT-555) / AbbVie, Ocrevus (ocrelizumab) / Roche, Biogen
Licensing / partnership: Please, make the @Roche /@genentech @_RocheUK + @abbvie @AbbVieUS @abbvieuk partnership a reality! Including a Ph III of #ocrelizumab + #elezanumab would be amazing 🤓😎#MSologyGoals (Twitter) - Feb 19, 2020
- ||| elezanumab (ABT-555) / AbbVie, Ocrevus (ocrelizumab) / Roche, Biogen
Clinical: Sending bills. This caused me a lot of undo stress and my husband. I wouldn’t go through that process again or recommend it. Now I’m on #Ocrevus and in a clinical trial for the #remyelination medication #elezanumab. (Twitter) - Feb 5, 2020
- ||| elezanumab (ABT-555) / AbbVie, Ocrevus (ocrelizumab) / Roche, Biogen
Clinical: However, after starting the clinical trial for elezanumab I didn’t observe this off label benefit after my Ocrevus infusion. The slight puffiness and up and downs of my Hashimotos came that month like it usually does. However, by tsh is low, but TPO very high. (Twitter) - Feb 3, 2020